Zogenix Provides Corporate Update and Reports First Quarter 2017 Financial Results

EMERYVILLE, Calif., May 04, 2017 (GLOBE NEWSWIRE) — Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today provided a corporate update and announced financial results for the first quarter ended March 31, 2017.